Intercept Pharma Slips 28% As FDA Panel Votes Against Liver Disease Drug
Intercept Pharmaceutics, Inc (ICPT) shares are down almost 28% on Monday, after an FDA advisory panel voted against Intercept's drug obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH.
Source: rttnews.com